IBD Stock Ratings Get Even Better With These Upgrades

Why It Matters

By tightening the peer groups and using richer data, IBD’s ratings become more reliable, helping retail and professional investors identify truly strong stocks and avoid low‑quality or mis‑rated securities.

Key Takeaways

• IBD separates stocks from ETFs, ETNs, and closed‑end funds in ratings
• Liquidity and market‑cap thresholds filter out micro‑caps and illiquid stocks
• SPACs are rated only after completing their acquisitions
• FactSet data powers updated Relative Strength, EPS and SMR ratings

Pulse Analysis

Investor’s Business Daily has long been a staple for traders seeking quantitative stock rankings, but the explosion of exchange‑traded funds and the rise of private‑equity‑backed companies have strained its original methodology. By carving out ETFs, ETNs and closed‑end funds into a distinct comparison universe, IBD eliminates the apples‑to‑oranges problem that could inflate a stock’s percentile rank. This separation, coupled with new liquidity and market‑capitalization thresholds, ensures that only institutional‑quality equities compete for top‑tier ratings, sharpening the focus for investors hunting genuine market leaders.

The overhaul also modernizes the core rating engines. Relative Strength now evaluates 12‑month, 6‑month and 3‑month windows with additional data points, making the metric more responsive to recent price swings. Earnings‑per‑share and Sales‑Margins‑ROE scores have migrated to FactSet, aligning IBD’s numbers with industry‑standard data and expanding coverage to capture recent quarterly growth. SPACs, historically volatile, are excluded until they close a deal, preventing speculative noise from crowding the top percentiles. Adding Average True Range to the Accumulation/Distribution rating further refines the view of institutional buying pressure, while the Composite rating now measures off‑high performance over three years, offering a longer‑term perspective.

These enhancements position IBD as a more credible alternative to pure‑price‑action tools and traditional analyst reports. Retail investors gain a cleaner, data‑driven lens to spot high‑quality opportunities, while advisors can rely on more consistent metrics when constructing client portfolios. As the market continues to evolve with new asset classes and trading strategies, IBD’s commitment to iterative rating improvements signals a forward‑looking approach that could set a new benchmark for public‑facing stock analytics.